This website uses cookies
Read our Privacy policy and Terms of use for more information.
The latest news, articles, and resources, sent to your inbox weekly.
GLP1
+2

Jun 16, 2026
•
9 min read
Survodutide and pemvidutide keep landing below 20% on body weight — while clearing liver fat at rates no pure GLP-1 can touch. A dispatch on the ADA 2026 readouts, and the case for grading incretins on the right organ.

CV
+1

Jun 13, 2026
•
7 min read
A new natural-history study watched atherosclerosis grow in untreated, low-risk adults over five years — and quietly made the strongest case I’ve seen in years for treating LDL early and aggressively.

CV
+2

Jun 9, 2026
•
10 min read
Lp(a) drives heart attacks, strokes, and aortic stenosis in one in five people. Statins don’t touch it. Diet doesn’t move it. After six decades of therapeutic silence, 2026 is the year the verdict finally arrives — and a single gene edit may make the problem history.
